Your browser is no longer supported. Please, upgrade your browser.
Settings
MRK Merck & Co., Inc. daily Stock Chart
MRK [NYSE]
Merck & Co., Inc.
IndexDJIA S&P500 P/E39.86 EPS (ttm)1.53 Insider Own0.10% Shs Outstand2.70B Perf Week-2.26%
Market Cap164.48B Forward P/E13.45 EPS next Y4.54 Insider Trans-11.56% Shs Float2.69B Perf Month3.20%
Income4.18B PEG5.95 EPS next Q1.03 Inst Own75.90% Short Float0.68% Perf Quarter11.69%
Sales40.73B P/S4.04 EPS this Y29.20% Inst Trans-0.68% Short Ratio1.63 Perf Half Y8.52%
Book/sh12.49 P/B4.89 EPS next Y7.31% ROA1.80% Target Price69.02 Perf Year-4.16%
Cash/sh2.73 P/C22.39 EPS next 5Y6.70% ROE4.30% 52W Range52.83 - 66.41 Perf YTD8.46%
Dividend1.92 P/FCF1134.32 EPS past 5Y-1.90% ROI8.70% 52W High-8.10% Beta0.79
Dividend %3.15% Quick Ratio1.10 Sales past 5Y-3.20% Gross Margin68.60% 52W Low15.52% ATR0.97
Employees69000 Current Ratio1.40 Sales Q/Q6.40% Oper. Margin13.60% RSI (14)52.19 Volatility1.34% 1.41%
OptionableYes Debt/Eq0.70 EPS Q/Q-51.60% Profit Margin3.90% Rel Volume0.74 Prev Close61.03
ShortableYes LT Debt/Eq0.64 EarningsJul 31 BMO Payout326.40% Avg Volume11.15M Price61.03
Recom2.00 SMA200.30% SMA502.70% SMA2004.24% Volume0 Change0.00%
Apr-23-18Upgrade Goldman Neutral → Buy
Apr-17-18Upgrade Morgan Stanley Equal-Weight → Overweight
Apr-05-18Upgrade Barclays Equal Weight → Overweight $62 → $64
Mar-12-18Upgrade Leerink Partners Mkt Perform → Outperform
Feb-14-18Reiterated Leerink Partners Mkt Perform $67 → $66
Feb-07-18Reiterated Morgan Stanley Equal-Weight $60 → $63
Jan-16-18Upgrade SunTrust Hold → Buy
Nov-28-17Resumed BofA/Merrill Buy $64
Nov-24-17Reiterated Deutsche Bank Hold $62 → $59
Oct-31-17Upgrade Jefferies Underperform → Hold
Oct-30-17Downgrade SunTrust Buy → Hold
Oct-30-17Downgrade Morgan Stanley Overweight → Equal-Weight
Oct-30-17Downgrade Barclays Overweight → Equal Weight $72 → $62
Oct-18-17Upgrade Citigroup Neutral → Buy
Aug-09-17Upgrade HSBC Securities Reduce → Hold
Jul-31-17Reiterated UBS Buy $70 → $72
Jan-13-17Initiated Bryan Garnier Buy
Jan-12-17Upgrade Piper Jaffray Neutral → Overweight
Jan-12-17Upgrade Morgan Stanley Equal-Weight → Overweight
Jan-12-17Upgrade Guggenheim Neutral → Buy
Jun-20-18 07:35AM  What GEs stock being replaced by Walgreens in the Dow Jones Industrial Average may mean MarketWatch
04:26AM  [$$] Wednesday's European Corporate Roundup The Wall Street Journal
02:02AM  Latecomer Sanofi looks to catch next wave of cancer therapies Reuters
Jun-19-18 08:16AM  Better Buy: Celgene Corporation vs. Merck Motley Fool
Jun-18-18 06:00PM  In China, Baijiu and HPV Vaccines Have Something in Common Bloomberg
07:00AM  The Blockchain Revolution Has Just Begun InvestorPlace
06:00AM  5 Drug Stocks With Fat Payouts Investopedia
Jun-15-18 11:52AM  7 Perfect Dividend Stocks InvestorPlace
10:56AM  Affimed Shares Slide On Updated Hodgkin Lymphoma Drug Combo Data Benzinga
10:13AM  Top Ranked Income Stocks to Buy for June 15th Zacks
09:27AM  Pharma Stock Roundup: LLY/AZN Alzheimer's Drug Fails, MRK's Keytruda Wins Approvals Zacks
09:25AM  Dow 30 Stock Roundup: Caterpillar Raises Dividend, Merck's Keytruda Gets FDA Nod Zacks
Jun-14-18 09:09PM  Does Merck & Co Inc.s (NYSE:MRK) PE Ratio Signal A Selling Opportunity? Simply Wall St.
12:05PM  3 Stocks Raising Hopes in Troubled Large-Cap Pharma Industry InvestorPlace
08:30AM  Merck's Keytruda Gets FDA Nod for 2nd Lymphoma Indication Zacks
08:11AM  Benzinga's Daily Biotech Pulse: FDA Nods For Teligent And Keytruda, Sonoma's Q4 Miss, Sage Inks Deal With Japan's Shionogi Benzinga
06:54AM  Merck (MRK): Moving Average Crossover Alert Zacks
Jun-13-18 05:00PM  China's Vaccine Tourists Drain Hong Kong's Supply of Cancer Drug Bloomberg
04:06PM  FDA Approves Mercks KEYTRUDA® (pembrolizumab) for Treatment of Refractory or Relapsed Primary Mediastinal Large B-Cell Lymphoma (PMBCL) Business Wire
10:37AM  Merck's (MRK) Keytruda Gets FDA Approval for Cervical Cancer Zacks
06:45AM  FDA Grants Priority Review to Mercks Supplemental Biologics License Application (sBLA) for GARDASIL®9 in Women and Men Ages 27 to 45 for the Prevention of Certain HPV-Related Cancers and Diseases Business Wire
Jun-12-18 04:06PM  FDA Approves Mercks KEYTRUDA® (pembrolizumab) for Previously Treated Patients with Recurrent or Metastatic Cervical Cancer Whose Tumors Express PD-L1 (CPS Greater Than or Equal to 1) Business Wire
10:24AM  Lilly & AstraZeneca Scrap Studies on Alzheimer's Candidate Zacks
09:25AM  Alzheimer's Research Stumbles Again: What's the Road Ahead? Zacks
07:14AM  Top Ranked Income Stocks to Buy for June 12th Zacks
Jun-11-18 01:12PM  Mega Caps Are Soaring in June: 3 Top-Ranked Stocks on Sale InvestorPlace
Jun-08-18 12:20PM  The CEO Action for Diversity and Inclusion Turns Two Fortune
09:14AM  An Unlikely Biotech Investor: The Government Forbes
08:05AM  The Zacks Analyst Blog Highlights: Merck, Occidental Petroleum, Capital One Financial, Kimberly-Clark and Allstate Zacks
Jun-07-18 02:47PM  Top Analyst Reports for Merck, Occidental Petroleum & Capital One Financial Zacks
09:30AM  Is Merck & Co. (MRK) Outperforming Other Medical Stocks This Year? Zacks
Jun-06-18 08:29AM  ASCO Ends: Winners & Losers at the Key Cancer Research Event Zacks
Jun-05-18 05:26PM  Sanofi, Merck and J&J Tout Lower Drug Prices TheStreet.com
12:16PM  Pharma Giant Merck Is Planning for a Brexit Supply Blackout Bloomberg
12:16PM  Merck Is Said to Prepare for Supply Blackout in Brexit Planning Bloomberg
10:56AM  Merck Presents Positive Melanoma Data on Keytruda at ASCO Zacks
Jun-04-18 07:45PM  Research Yields Progress Against Lung Cancer The Wall Street Journal
05:00PM  LYNPARZA® (olaparib) in Combination with Abiraterone Delayed Disease Progression in Metastatic Castration-Resistant Prostate Cancer Business Wire
11:55AM  Merck Higher on Lung Cancer Data TheStreet.com
10:57AM  Merck's (MRK) Keytruda Lung Cancer Data in Focus at ASCO Zacks
09:39AM  3 Stocks Raising Hopes in Troubled Large-Cap Pharma Industry Zacks
09:00AM  Two Year Update of Pivotal JAVELIN Merkel 200 Trial Shows Continued Durable Responses with BAVENCIO® (avelumab) CNW Group
08:30AM  Today's Research Reports on Trending Tickers: Merck & Co. and Pfizer Inc. ACCESSWIRE
08:16AM  Merck's Keytruda shows promise in treating advanced melanoma Reuters
07:45AM  Mercks KEYTRUDA® (pembrolizumab) Showed Promising Anti-Tumor Activity in Patients with Advanced Small Cell Lung Cancer (SCLC) in Phase 2 KEYNOTE-158 Study Business Wire
07:41AM  Merck announces positive results for Keytruda in melanoma trial MarketWatch
07:30AM  Mercks KEYTRUDA® (pembrolizumab) Demonstrated Long-Term Survival Benefit Based on Four and Five Years of Follow-Up from Two Pivotal Studies in Advanced Melanoma Business Wire
Jun-03-18 06:00PM  Eisai and Merck Announce Data at 2018 ASCO Annual Meeting from Investigational Studies of LENVIMA® (lenvatinib) and KEYTRUDA® (pembrolizumab) Combination Therapy in Four Different Tumor Types PR Newswire
11:57AM  Merck's Keytruda extends lung cancer survival in 2 trials Reuters
09:00AM  Mercks KEYTRUDA® (pembrolizumab) Showed Overall Response Rate of Nearly 40 Percent as First-Line Therapy in Patients with Advanced Clear Cell Renal Cell Carcinoma (RCC) in Phase 2 KEYNOTE-427 Study Business Wire
08:30AM  Merck Presents Update on Tepotinib in Advanced Lung Cancer at ASCO 2018 CNW Group
07:30AM  Mercks KEYTRUDA® (pembrolizumab) Plus Chemotherapy Significantly Improved Overall Survival in First-Line Treatment of Metastatic Squamous Non-Small Cell Lung Cancer in Phase 3 KEYNOTE-407 Study Business Wire
07:30AM  Merck's Keytruda shown to extend lung cancer survival in 2 trials Reuters
07:30AM  Lung Cancer Drug From Merck Solidifies Lead in Crowded Field Bloomberg
07:30AM  KEYTRUDA® (pembrolizumab) Monotherapy Significantly Improved Overall Survival in KEYNOTE-042 Study as First-Line Treatment for Locally Advanced or Metastatic NSCLC Patients Whose Tumors Expressed PD-L1 (TPS 1%) Business Wire
Jun-02-18 07:30AM  Roche drugs show limited benefit in lung, breast cancer trials Reuters
May-31-18 11:30PM  [$$] Big Pharma on mission to bring immunotherapy to more patients Financial Times
02:14PM  Pfizer Inc. Stock Desperately Needs a Viagra-Like Boost InvestorPlace
08:53AM  Merck and Premier Inc. Collaborating to Help Reduce Clostridium difficile (C. diff) Infection Business Wire
12:18AM  HPV Vaccine Seller in China Propels Owners Up Billionaires List Bloomberg
May-30-18 09:03PM  Read This Before You Buy Immuno-Oncology Stocks Motley Fool
02:25PM  7 Reliable Stocks For An Uncertain Market Investopedia
01:33PM  Trump says drugmakers are going to announce massive voluntary price cuts in two weeks CNBC
May-29-18 02:54PM  20 Cryptocurrencies to Consider If You Can Stomach It InvestorPlace
May-25-18 10:51AM  Eisai and Merck Announce Update on Lenvatinib sNDA Review Zacks
09:19AM  Benzinga's Daily Biotech Pulse: Biomarin Gets FDA Nod, Amarin Settles with Teva, Merck's Cancer Drug Review Extended Benzinga
May-24-18 07:34PM  Eisai And Merck Provide Update on Supplemental New Drug Application (sNDA) for Lenvatinib in First-Line Unresectable Hepatocellular Carcinoma PR Newswire
11:00AM  Merck's Keytruda Shows Survival Benefit in Squamous NSCLC Zacks
May-23-18 06:32PM  Trump Administration Ups Dose Of Shame As TV Drug Ad Policy Idea Moves Forward TheStreet.com
05:56PM  Why Big Pharma is finally discovering the Bay Area American City Business Journals
04:43PM  Ebola patients slip out of Congo hospital as medics try to curb outbreak Reuters
03:24PM  7 S&P 500 Companies Doing Right for Employees InvestorPlace
11:57AM  Merck's cancer drug Keytruda notches another trial success Reuters
10:55AM  Why the world needs more than one Ebola vaccine Reuters
07:46AM  Three Ebola patients escape Congo quarantine, medics race to control outbreak Reuters
07:30AM  Mercks experimental and unlicensed Ebola vaccine is being used in latest outbreak MarketWatch
06:45AM  Mercks KEYTRUDA® (pembrolizumab) Significantly Improved Overall Survival and Progression-Free Survival as First-Line Treatment for Squamous Non-Small Cell Lung Cancer (NSCLC) in Pivotal Phase 3 KEYNOTE-407 Trial Business Wire
06:11AM  Three Ebola patients escape quarantine in Congo, two later die - MSF Reuters
May-22-18 02:21PM  Merck Announces Third-Quarter 2018 Dividend Business Wire
12:25AM  [$$] Ebola Vaccination Begins in Democratic Republic of Congo The Wall Street Journal
May-21-18 04:53PM  [$$] Ebola Vaccination Begins in Democratic Republic of Congo The Wall Street Journal
10:49AM  Factbox - From sterling crises to Brexit, the tests of Bank of England bosses Reuters
10:35AM  Congo begins giving experimental Ebola vaccine to medics Reuters
09:40AM  7 Blue-Chip Stocks That Arent Blue Chips at All InvestorPlace
May-20-18 07:42AM  Congo to begin Ebola vaccinations on Monday - health ministry Reuters
May-18-18 11:13AM  3 Dow Stocks to Buy With Dividends Yielding More Than 3% Motley Fool
06:00AM  Why J&J's Stock May Plunge 10% Investopedia
May-17-18 11:27AM  Investors Need to Adopt a Different Mindset for Big Pharma and Biotech Stocks InvestorPlace
10:03AM  Roche Tecentriq Combo Achieves Longer Overall Survival Rate Zacks
09:16AM  The Zacks Analyst Blog Highlights: Home Depot, Merck, Raytheon, Eaton and Sun Life Financial Zacks
May-16-18 06:10PM  Roche immunotherapy combination increases lung cancer survival-study Reuters
05:32PM  Merck's Keytruda boosts response in hard-to-treat lung cancer Reuters
05:05PM  New Data from Mercks Leading Immuno-Oncology Clinical Development Program in Over 25 Tumor Types to Be Presented at 2018 ASCO Annual Meeting Business Wire
02:37PM  MARKETS: Russell 2000 hits all-time high; Walmart earnings on deck; oil prices reverse; healthcare stocks in focus Yahoo Finance Video
10:54AM  Top Analyst Reports for Home Depot, Merck & Raytheon Zacks
May-15-18 01:31PM  Ebola Vaccine Headed to Congo to Help Contain Outbreak The Wall Street Journal
10:32AM  Merck KGaA (MKGAF) Q1 Earnings and Revenues Decline Y/Y Zacks
08:00AM  Free Stock Performance Review on Pfizer and Three More Drug Makers Stocks ACCESSWIRE
03:44AM  Merck KGaA Sees Profit Falling on Liquid Crystals Struggle Bloomberg Video
03:44AM  Merck KGaA Sees Profit Falling on Liquid Crystals Struggle Bloomberg
Merck & Co., Inc. provides healthcare solutions worldwide. It operates in four segments: Pharmaceutical, Animal Health, Healthcare Services, and Alliances. The company offers therapeutic and preventive agents to treat cardiovascular diseases, type 2 diabetes, asthma, nasal allergy symptoms, allergic rhinitis, chronic hepatitis C virus, HIV-1 infection, fungal, intra-abdominal infections, hypertension, arthritis and pain, inflammatory, osteoporosis, and fertility diseases. It also provides neuromuscular blocking agents; anti-bacterial products; cholesterol modifying medicines; and vaginal contraceptive products. In addition, the company offers products to prevent chemotherapy-induced and post-operative nausea and vomiting; treat brain tumors, and metastatic non-small-cell lung cancer; prevent diseases caused by human papillomavirus; and vaccines for measles, mumps, rubella, varicella, shingles, rotavirus gastroenteritis, and pneumococcal diseases. Further, it offers antibiotic and anti-inflammatory drugs to treat infectious and respiratory diseases, fertility disorders, and pneumonia in cattle, horses, and swine; vaccines for poultry; parasiticide for sea lice in salmon; and antibiotics and vaccines for fishes. The company also provides companion animal products, such as ointments; diabetes mellitus treatment for dogs and cats; anthelmintic products; fluralaner products to treat fleas and ticks in dogs; and products for protection against bites from fleas, ticks, mosquitoes, and sandflies. It has collaborations with Pfizer Inc., AstraZeneca PLC, Bayer AG, Eisai Co., Ltd., and IO Biotech. It serves drug wholesalers and retailers, hospitals, government agencies and entities, physicians, physician distributors, veterinarians, distributors, animal producers, and managed health care providers. The company was founded in 1891 and is headquartered in Kenilworth, New Jersey.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Schechter Adam HEVP & Pres-Global Human HealthJun 18Option Exercise36.56100,0003,656,000100,000Jun 19 10:55 AM
Schechter Adam HEVP & Pres-Global Human HealthJun 18Sale61.0034,0942,079,78562,766Jun 19 10:55 AM
Schechter Adam HEVP & Pres-Global Human HealthJun 18Sale61.00100,0006,100,1600Jun 19 10:55 AM
Gerberding Julie L.EVP Strat Comm, Gl Pub PolicyMay 15Sale59.669,972594,96345,717May 16 12:33 PM
Watson AshleySVP Chief Ethics & Com OfficerMay 01Option Exercise0.0010,441012,783May 02 12:19 PM
Chattopadhyay SanatExe V-P & Pres. MMDMay 01Option Exercise0.004,009052,609May 02 12:18 PM
Karachun Rita ASr. VP Fince-Global ControllerMay 01Option Exercise0.003,007022,205May 02 12:18 PM
GRADDICK WEIR MIRIAN MExe V-P, HRApr 16Sale58.0024,0001,392,00080,433Apr 17 05:56 PM
WEEKS WENDELL PDirectorFeb 09Option Exercise38.045,000190,2005,100Feb 09 04:48 PM
DeLuca Richard R.EVP&Pres, Merck Animal HealthFeb 09Option Exercise0.008,572045,780Feb 09 04:48 PM
WEEKS WENDELL PDirectorFeb 09Sale53.575,000267,833100Feb 09 04:48 PM
Schechter Adam HEVP & Pres-Global Human HealthJan 16Option Exercise36.5650,9941,864,34150,994Jan 16 05:13 PM
GRADDICK WEIR MIRIAN MExe V-P, HRJan 16Option Exercise44.3052,0002,303,600153,484Jan 16 05:12 PM
Holston Michael JEVP, General CounselJan 16Sale61.6312,500770,37549,092Jan 16 05:13 PM
Schechter Adam HEVP & Pres-Global Human HealthJan 16Sale61.6350,6083,118,97162,766Jan 16 05:13 PM
Schechter Adam HEVP & Pres-Global Human HealthJan 16Sale61.6350,9943,142,7600Jan 16 05:13 PM
GRADDICK WEIR MIRIAN MExe V-P, HRJan 16Sale61.6360,0003,697,80093,484Jan 16 05:12 PM
GRADDICK WEIR MIRIAN MExe V-P, HRJan 12Sale58.005,000290,000101,484Jan 16 05:12 PM
GLOCER THOMAS HDirectorNov 08Option Exercise38.045,000190,20010,100Nov 09 03:52 PM
GLOCER THOMAS HDirectorNov 08Sale56.205,000280,9835,100Nov 09 03:52 PM